by Meriem Bouslouk-Marx | 28 Feb 2022
Oral and maxillofacial surgery was one major discipline during my last years of dental medicine at the Friedrich Schiller University in Jena. I was intrigued by the strange names of diseases and syndromes such as Hodgkin’s, non-Hodgkin’s and... 
by Meriem Bouslouk-Marx | 15 Mar 2021
Advanced Therapy Medicinal Products (ATMPs) especially those for the treatment of rare diseases are innovative but also very expensive medicines. For payers, they constitute a new challenge. How will financing advanced therapies work in Germany? Two invited experts... 
by Meriem Bouslouk-Marx | 15 Jul 2020
In July 2020, the International Federation of Pharmaceutical Manufacturers & Associations IFPMA, the European Federation of Pharmaceutical Industries and Associations EFPIA and the German Association of Research-Based Pharmaceutical Companies vfa organised an... 
by Meriem Bouslouk-Marx | 1 Dec 2019
Following the invitation of Sindusfarma (Syndicate of the Pharmaceutical Products Industry in the State of São Paulo) and Anvisa (Brazilian Health Regulatory Agency), stakeholders met to discuss Brazil’s challenges with advanced therapies. The two days with... 
by Meriem Bouslouk-Marx | 5 Jul 2019
Professor Sami Haddadin, Technical University of Munich, started with a historical introduction of Artificial Intelligence (AI). The Dartmouth summer research project on AI in 1956 introduced AI as a discipline. He acknowledged cognitive improvements after the first... 
by Meriem Bouslouk-Marx | 28 May 2019
Under the patronage of René Röspel, Social Democratic Party of Germany (SPD) parliamentary group, a multi-stakeholder session on rare diseases took place at the Bundestag. This platform offered the audience a discourse with representatives from policy, patients,...